Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 354

1.

Correction: The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort.

Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, Pala V, Weiderpass E, Margall N, Dillner J, Gram IT, Tjønneland A, Munk C, Palli D, Khaw KT, Overvad K, Clavel-Chapelon F, Mesrine S, Fournier A, Fortner RT, Ose J, Steffen A, Trichopoulou A, Lagiou P, Orfanos P, Masala G, Tumino R, Sacerdote C, Polidoro S, Mattiello A, Lund E, Peeters PH, Bueno-de-Mesquita HB, Ramón Quirós J, Sánchez MJ, Navarro C, Barricarte A, Larrañaga N, Ekström J, Lindquist D, Idahl A, Travis RC, Merritt MA, Gunter MJ, Rinaldi S, Tommasino M, Franceschi S, Riboli E, Castellsagué X.

PLoS One. 2016 Mar 8;11(3):e0151427. doi: 10.1371/journal.pone.0151427. eCollection 2016.

2.

The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort.

Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, Pala V, Weiderpass E, Margall N, Dillner J, Gram IT, Tjønneland A, Munk C, Palli D, Khaw KT, Overvad K, Clavel-Chapelon F, Mesrine S, Fournier A, Fortner RT, Ose J, Steffen A, Trichopoulou A, Lagiou P, Orfanos P, Masala G, Tumino R, Sacerdote C, Polidoro S, Mattiello A, Lund E, Peeters PH, Bueno-de-Mesquita HB, Quirós JR, Sánchez MJ, Navarro C, Barricarte A, Larrañaga N, Ekström J, Lindquist D, Idahl A, Travis RC, Merritt MA, Gunter MJ, Rinaldi S, Tommasino M, Franceschi S, Riboli E, Castellsagué X.

PLoS One. 2016 Jan 25;11(1):e0147029. doi: 10.1371/journal.pone.0147029. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0151427.

3.

Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.

Van Damme P, Bonanni P, Bosch FX, Joura E, Krüger Kjaer S, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M.

Vaccine. 2016 Feb 3;34(6):757-61. doi: 10.1016/j.vaccine.2015.12.063. Epub 2016 Jan 6.

4.

Secular trends of HPV genotypes in invasive cervical cancer in Cali, Colombia 1950-1999.

Sanchez GI, Bravo LE, Hernandez-Suarez G, Tous S, Alemany L, de Sanjose S, Bosch FX, Muñoz N.

Cancer Epidemiol. 2016 Feb;40:173-8. doi: 10.1016/j.canep.2015.12.008. Epub 2016 Jan 6.

PMID:
26771314
5.

Role of Human Papillomavirus in Penile Carcinomas Worldwide.

Alemany L, Cubilla A, Halec G, Kasamatsu E, Quirós B, Masferrer E, Tous S, Lloveras B, Hernández-Suarez G, Lonsdale R, Tinoco L, Alejo M, Alvarado-Cabrero I, Laco J, Guimerà N, Poblet E, Lombardi LE, Bergeron C, Clavero O, Shin HR, Ferrera A, Felix A, Germar J, Mandys V, Clavel C, Tzardi M, Pons LE, Wain V, Cruz E, Molina C, Mota JD, Jach R, Velasco J, Carrilho C, López-Revilla R, Goodman MT, Quint WG, Castellsagué X, Bravo I, Pawlita M, Muñoz N, Bosch FX, de Sanjosé S; HPV VVAP study group.

Eur Urol. 2016 Jan 4. pii: S0302-2838(15)01215-4. doi: 10.1016/j.eururo.2015.12.007. [Epub ahead of print]

PMID:
26762611
6.

Training in the prevention of cervical cancer: advantages of e-learning.

Company A, Montserrat M, Bosch FX, de Sanjosé S.

Ecancermedicalscience. 2015 Oct 8;9:580. doi: 10.3332/ecancer.2015.580. eCollection 2015.

7.

Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.

Georgalis L, de Sanjosé S, Esnaola M, Bosch FX, Diaz M.

Eur J Cancer Prev. 2015 Sep 15. [Epub ahead of print]

PMID:
26375246
8.

HPV-FASTER: broadening the scope for prevention of HPV-related cancer.

Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry KU, Poljak M, Kjaer SK, Meijer CJ, Garland SM, Salmerón J, Castellsagué X, Bruni L, de Sanjosé S, Cuzick J.

Nat Rev Clin Oncol. 2016 Feb;13(2):119-32. doi: 10.1038/nrclinonc.2015.146. Epub 2015 Sep 1. Review.

PMID:
26323382
9.

Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions.

Ibáñez R, Alejo M, Combalia N, Tarroch X, Autonell J, Codina L, Culubret M, Bosch FX, de Sanjosé S.

Biomed Res Int. 2015;2015:605375. doi: 10.1155/2015/605375. Epub 2015 Jun 9.

10.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.

Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

PMID:
26071347
11.

Screening of cervical cancer in Catalonia 2006-2012.

de Sanjosé S, Ibáñez R, Rodríguez-Salés V, Peris M, Roura E, Diaz M, Torné A, Costa D, Canet Y, Falguera G, Alejo M, Espinàs JA, Bosch FX.

Ecancermedicalscience. 2015 Apr 29;9:532. doi: 10.3332/ecancer.2015.532. eCollection 2015.

12.

Disagreement in high-grade/low-grade intraepithelial neoplasia and high-risk/low-risk HPV infection: clinical implications for anal cancer precursor lesions in HIV-positive and HIV-negative MSM.

Pimenoff VN, Félez-Sánchez M, Tous S, Clavero O, Godínez JM, Klaustermeier J, Saunier M, Molijn A, Alemany L, Quint W, Bosch FX, de Sanjosé S, McCloskey J, Bravo IG.

Clin Microbiol Infect. 2015 Jun;21(6):605.e11-9. doi: 10.1016/j.cmi.2015.02.009. Epub 2015 Feb 17.

PMID:
25700891
13.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.

14.

HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis.

Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, Bosch FX, de Sanjosé S, Trottier H.

Lancet Oncol. 2014 Nov;15(12):1319-31. doi: 10.1016/S1470-2045(14)70471-1. Epub 2014 Oct 16. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.

PMID:
25439690
15.

Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China).

Serrano B, Alemany L, Ruiz PA, Tous S, Lima MA, Bruni L, Jain A, Clifford GM, Qiao YL, Weiss T, Bosch FX, de Sanjosé S.

Cancer Epidemiol. 2014 Dec;38(6):748-56. doi: 10.1016/j.canep.2014.09.003. Epub 2014 Oct 8.

16.

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.

Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1997-2008. doi: 10.1158/1055-9965.EPI-14-0410.

17.

Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples.

Alemany L, Saunier M, Tinoco L, Quirós B, Alvarado-Cabrero I, Alejo M, Joura EA, Maldonado P, Klaustermeier J, Salmerón J, Bergeron C, Petry KU, Guimerà N, Clavero O, Murillo R, Clavel C, Wain V, Geraets DT, Jach R, Cross P, Carrilho C, Molina C, Shin HR, Mandys V, Nowakowski AM, Vidal A, Lombardi L, Kitchener H, Sica AR, Magaña-León C, Pawlita M, Quint W, Bravo IG, Muñoz N, de Sanjosé S, Bosch FX; HPV VVAP study group.

Eur J Cancer. 2014 Nov;50(16):2846-54. doi: 10.1016/j.ejca.2014.07.018. Epub 2014 Aug 21.

PMID:
25155250
18.

Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina.

Iljazović E, Mena M, Tous S, Alemany L, Omeragić F, Sadiković A, Clavero O, Vergara M, Bosch FX, de Sanjosé S.

Cancer Epidemiol. 2014 Oct;38(5):504-10. doi: 10.1016/j.canep.2014.06.004. Epub 2014 Aug 11.

PMID:
25130915
19.

Protecting the underscreened women in developed countries: the value of HPV test.

Ibáñez R, Autonell J, Sardà M, Crespo N, Pique P, Pascual A, Martí C, Fibla M, Gutiérrez C, Lloveras B, Moreno-Crespi J, Torrent A, Baixeras N, Alejo M, Bosch FX, de Sanjosé S.

BMC Cancer. 2014 Aug 8;14:574. doi: 10.1186/1471-2407-14-574.

20.

Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer.

Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M; Retrospective International Survey and HPV Time Trends Study Group; Retrospective International Survey and HPV Time Trends Study Group.

J Pathol. 2014 Dec;234(4):441-51. doi: 10.1002/path.4405. Epub 2014 Sep 12.

PMID:
25043390
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk